RBC Capital reports that newly updated clinicaltrials.gov records show that Gilead’s (GILD) Phase 1 study testing ‘1219, a next-generation longer-acting injectable integrase inhibitors, has been terminated after only four of the expected 30 patients were enrolled. The termination, which follows other setbacks for the HIV life cycle program of late, illustrates HIV life cycle challenges, says the analyst. However, with the Yeztugo launch in near-term focus and recent Biktarvy exclusivity extension providing “more cushion for development of next-gens,” RBC acknowledges a near-term impact on shares may be limited and it maintains a Sector Perform rating on Gilead shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Galapagos price target raised to $28 from $27 at RBC Capital
- Galapagos intends to wind down cell therapy business
- Gilead Sciences Completes Promising Study on Metastatic Colorectal Cancer Treatment
- Gilead, AstraZeneca, and Roche Data Signal New Growth in Cancer Drug Market
- Gilead presents new HIV research data at European AIDS Conference